CAB39 Polyclonal Antibody

Background:
Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).

Research Area: Cancer, Metabolism, Signal Transduction

Synonyms:
Cab39, CAB39, Calcium binding protein 39, Calcium-binding protein 39, CGI 66, CGI-66, CGI66, MO25 alpha, MO25, Mouse protein 25 alpha, Protein Mo25

Immunogen: Synthetic peptide of human CAB39

Swissprot: Q9Y376
Gene Accession: NP_057373

Calculated MW: 40 kDa

Purification Method: Affinity purification

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Concentration: 1.7 mg/mL
Dilution: WB 1:500-1:2000, IHC 1:50-1:200

Storage:
Store at -20°C. Avoid freeze / thaw cycles.